Oncology · Breast CancerTrial Updateclinicalmid-term

Study on Utidelone's Efficacy in HER-2 Negative Advanced Breast Cancer

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 6:04:30 AM

Assessment confidence: 92% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The ongoing trial of Utidelone in HER-2 negative advanced breast cancer could significantly influence its market positioning and competitive landscape. Positive outcomes may lead to increased investment and strategic focus on breast cancer therapies, impacting overall portfolio strategies. Regulatory context from MHRA (MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer) supports the near-term read. Assessment grounded in 3 ranked evidence items (3 high-relevance).

Strategic Assessment

Positive results could enhance the market potential for Utidelone, influencing strategic decisions regarding investment and development in breast cancer therapies. The strongest clinical anchor is Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer (ClinicalTrials.gov), sub-indication match (her2); mechanism alignment (her-2). Successful trial results could enhance Utidelone's market potential, potentially increasing revenue and market share against existing therapies in a competitive oncology landscape.

Competitive Pressure

The most relevant competitive pressure comes from The outcomes of this trial could impact the competitive positioning of Utidelone in the treatment landscape for advanced breast cancer, particularly against existing therapies..

Regulatory Outlook

Regulatory risk is concentrated around The trial's outcomes may lead to new regulatory filings, affecting approval timelines and labeling for Utidelone in the treatment of advanced breast cancer..

Key Risks

Elevated medium regulatory exposure for Beijing Biostar Pharmaceuticals Co., Ltd. could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

Successful trial results could enhance Utidelone's market potential, potentially increasing revenue and market share against existing therapies in a competitive oncology landscape.
Upside for Beijing Biostar Pharmaceuticals Co., Ltd. may improve if HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer (ClinicalTrials.gov) delivers favorable follow-through.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Positive results could enhance the market potential for Utidelone, influencing strategic decisions regarding investment and development in breast cancer therapies.

What Would Change This Assessment

This becomes more urgent if Monitor the trial results for Progression-Free Survival metrics and any subsequent regulatory filings.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAlow relevance
Patient population match (advanced)
FDA document
View source
FDA AP — ONTRUZANT (SUPPL)
FDAlow relevance
Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — ENHERTU (SUPPL)
FDAlow relevance
Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — PHESGO (SUPPL)
FDAlow relevance
Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — HERCEPTIN HYLECTA (SUPPL)
FDAlow relevance
Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — ONTRUZANT (SUPPL)
FDAlow relevance
Regulatory pathway relevance (bla)
FDA document
View source

Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (her2); Mechanism alignment (HER-2)
FDA document
View source
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (her2); Sponsor/company relevance (Roche)
FDA document
View source
Study of Voicing My CHOiCES as Tool for Advanced Care Planning in Young Adults With Cancer
ClinicalTrials.govlow relevance
Patient population match (advanced)
FDA document
View source

No evidence in this category.

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedhigh relevance
Sub-indication match (her2); Patient population match (advanced)
FDA document
View source
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedlow relevance
Patient population match (advanced)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Beijing Biostar Pharmaceuticals Co., Ltd.
Capecitabine

Commercial impact

medium

Successful trial results could enhance Utidelone's market potential, potentially increasing revenue and market share against existing therapies in a competitive oncology landscape.

Regulatory impact